AlenCiken

Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838

NASDAQ:IMUX   Immunic, Inc
Immunic , Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Study Meets Primary and Key Secondary Endpoints with High Statistical Significance

Statistically Significant Reduction of 62% and 70%

Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Multiple Sclerosis Patient Population -

- Company Also Reports Second Quarter 2020 Financial Results With $48.6 Million in Cash and Cash Equivalents -

https://finance.yahoo.com/news/immunic-i...